<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862431</url>
  </required_header>
  <id_info>
    <org_study_id>CR108166</org_study_id>
    <secondary_id>64565111EDI1001</secondary_id>
    <secondary_id>2016-001084-37</secondary_id>
    <nct_id>NCT02862431</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Men and Women With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of JNJ-64565111 in adult
      Men and Women (of non-child bearing potential) with Type 2 Diabetes Mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    manufacturing-related issues
  </why_stopped>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Day 72</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Incidence of Anti-JNJ-64565111 Antibodies as Measure of Immunogenicity</measure>
    <time_frame>Up to Day 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight</measure>
    <time_frame>Baseline, up to Day 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>Maximum observed plasma concentration (Cmax) will be assessed after first dose and last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>Tmax defined as actual sampling time to reach maximum observed analyte concentration will be assessed after first dose and last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Concentration from time zero to the last quantifiable concentration AUC(0-last)</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>AUC from time zero to the last quantifiable concentration will be assessed after first dose and after last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve over the dosing interval AUC(0-tau)</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>The AUC [0-tau] is the measure of the plasma drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption. AUC [0-tau] will be assessed after first dose and last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (t1/2)</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. t1/2 will be assessed after first dose and last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F)</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>The Oral Clearance (CL/F) is the clearance based on oral bioavailability. CL/F will be assessed after first dose and last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (V/F)</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>Apparent volume of distribution will be assessed after first dose and last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Rate Constant (K)</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>Terminal rate constant will be assessed after first dose and last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration over the dosing interval at steady state (Caverage,ss)</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>The average concentration over the dosing interval at steady state, calculated as AUC(0-tau)/tau and will be assessed after last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Concentration (Cmin)</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>The Cmin is the minimum observed plasma concentration over the dosing interval at steady state. Cmin will be assessed after last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve from time zero extrapolated to infinity AUC(0-inf)</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>AUC from time zero extrapolated to infinity will be assessed after last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio</measure>
    <time_frame>Up to Day 72</time_frame>
    <description>Accumulation ratio calculated as AUC(0-tau), Day 22 / AUC(0-tau), Day 1 will be assessed after last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure</measure>
    <time_frame>Baseline, up to Day 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate</measure>
    <time_frame>Baseline, up to Day 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for 24-hour Mean Plasma Glucose</measure>
    <time_frame>Baseline, Day 26</time_frame>
    <description>Mean plasma glucose defined as the total and/or incremental area under the concentration (AUC) time curve over 0 to 24 hours, divided by 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Baseline, up to Day 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, up to Day 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Fasting Lipids</measure>
    <time_frame>Baseline, up to Day 72</time_frame>
    <description>Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein cholesterol (VLDL-C), triglycerides and free fatty acids will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Secretion</measure>
    <time_frame>Baseline, Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Sensitivity</measure>
    <time_frame>Baseline, Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for C-peptide</measure>
    <time_frame>Baseline, Day 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Glucagon</measure>
    <time_frame>Baseline, Day 26</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (JNJ-64565111 2.5 nmol/kg or Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in ratio of 3:1 will receive 2.5 Nanomole Per Kilogram (nmol/kg) JNJ-64565111 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (JNJ-64565111 3 nmol/kg or Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in ratio of 3:1 will receive 3.0 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (JNJ-64565111 3.5 nmol/kg or Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in ratio of 3:1 will receive 3.5 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (JNJ-64565111 Repeat or Lower Dose or Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in ratio of 3:1 will receive a dose of JNJ-64565111 or placebo that would be a repeat or lower dose level previously assessed as well-tolerated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64565111</intervention_name>
    <description>Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.</description>
    <arm_group_label>Cohort 1 (JNJ-64565111 2.5 nmol/kg or Placebo)</arm_group_label>
    <arm_group_label>Cohort 2 (JNJ-64565111 3 nmol/kg or Placebo)</arm_group_label>
    <arm_group_label>Cohort 3 (JNJ-64565111 3.5 nmol/kg or Placebo)</arm_group_label>
    <arm_group_label>Cohort 4 (JNJ-64565111 Repeat or Lower Dose or Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.</description>
    <arm_group_label>Cohort 1 (JNJ-64565111 2.5 nmol/kg or Placebo)</arm_group_label>
    <arm_group_label>Cohort 2 (JNJ-64565111 3 nmol/kg or Placebo)</arm_group_label>
    <arm_group_label>Cohort 3 (JNJ-64565111 3.5 nmol/kg or Placebo)</arm_group_label>
    <arm_group_label>Cohort 4 (JNJ-64565111 Repeat or Lower Dose or Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Type 2 Diabetes Mellitus (T2DM) at least 3 months prior to Screening

          -  On a stable treatment regimen at least 3 months prior to Screening of (1) diet and
             exercise, or (2) metformin monotherapy (at a dose of at least 1,000 milligram (mg) per
             day)

          -  Blood pressure between 90 and 140 millimeter of mercury (mmHg) systolic, inclusive,
             and between 60 and 100 mmHg diastolic, inclusive at Screening (sitting) and Day -2
             (supine). If blood pressure is out of range, up to 2 repeated assessments are
             permitted

          -  HbA1c greater than or equal to 6.5% and less than 8.5% at Screening

          -  Females of non-childbearing potential

        Exclusion Criteria:

          -  History of, or currently active, significant illness or medical disorders, including
             cardiovascular disease (including cardiac arrhythmias, myocardial infarction, stroke,
             peripheral vascular disease), hematological disease (example, von Willebrand's disease
             or other bleeding disorders), respiratory disease, hepatic or gastrointestinal
             disease, neurological or psychiatric disease, ophthalmologic disorders, neoplastic
             disease, skin disorder, renal disorder, or any other illness that the Principal
             Investigator (PI) considers should exclude the participant or that could interfere
             with the interpretation of the study results

          -  Previous surgical treatment for obesity (example, gastric bypass, gastric banding)

          -  History of diabetic neuropathy with signs of gastroparesis and/or known proliferative
             retinopathy or maculopathy

          -  History or current diagnosis of acute or chronic pancreatitis

          -  History of an invasive cardiovascular surgical procedure including, but not limited
             to, coronary artery bypass graft (CABG), or percutaneous coronary intervention (PCI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

